Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer
AR Parikh, EE Van Seventer, G Siravegna… - Clinical Cancer …, 2021 - AACR
Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
M Garcia-Pardo, M Makarem, JJN Li, D Kelly… - British Journal of …, 2022 - nature.com
In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …
revolutionised the management of patients with solid tumours. Recent advances in the …
Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer
J Yang, Y Gong, VK Lam, Y Shi, Y Guan, Y Zhang… - Cell death & …, 2020 - nature.com
Identifying locoregional gastric cancer patients who are at high risk for relapse after
resection could facilitate early intervention. By detecting molecular residual disease (MRD) …
resection could facilitate early intervention. By detecting molecular residual disease (MRD) …
[HTML][HTML] Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions
S Chakrabarti, CY Peterson, D Sriram… - World journal of …, 2020 - ncbi.nlm.nih.gov
Colon cancer continues to be one of the leading causes of mortality and morbidity
throughout the world despite the availability of reliable screening tools and effective …
throughout the world despite the availability of reliable screening tools and effective …
[HTML][HTML] Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions
YK Chae, MS Oh - Journal of thoracic oncology, 2019 - Elsevier
Advances in DNA sequencing methods have significantly expanded the potential clinical
applications of analyzing circulating tumor DNA (ctDNA). This genetic information can …
applications of analyzing circulating tumor DNA (ctDNA). This genetic information can …
[HTML][HTML] Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
V Caputo, F Ciardiello, CM Della Corte… - … of targeted anti-tumor …, 2023 - ncbi.nlm.nih.gov
Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful
tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring …
tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring …
The promise of circulating tumor DNA (ctDNA) in the management of early-stage colon cancer: a critical review
Simple Summary Currently, the treatment for localized colon cancer consists of surgery and,
if the presence of residual cancer cells is suspected, chemotherapy following the surgery …
if the presence of residual cancer cells is suspected, chemotherapy following the surgery …
Molecular residual disease and adjuvant trial design in solid tumors
M Coakley, I Garcia-Murillas, NC Turner - Clinical Cancer Research, 2019 - AACR
Advances in diagnosis and treatment have resulted in a high rate of survival for many
patients with early-stage cancers. However, identifying who is at ongoing risk of relapse …
patients with early-stage cancers. However, identifying who is at ongoing risk of relapse …